FREE CPD EDUCATION PROGRAM
TargeT2D: Identifying high-risk patients with established T2D who may benefit from clinical review
A three-tiered CPD and quality improvement program for clinicians and clinics targeting treatment intensification in high-risk patients with established T2D. Includes a live webinar, CPD Shorts and a supported patient identification activity.
About this program
Some high-risk patients with established T2D may remain above their individualised glycaemic target despite advanced glucose-lowering therapy,³ while others may be overdue for HbA1c assessment.⁴⁺⁵ Proactively identifying these patients and facilitating timely clinical review can help optimise their diabetes management.
TargeT2D is a CPD-accredited patient identification program for general practice that combines clinician education with a structured, practice-led process to identify and review patients with established T2D on advanced glucose-lowering therapy. The program supports reassessment and optimisation of individualised management for these patients, with the aim of reducing their risk of diabetes-related complications.
Getting started
GPs: register for the live webinar, or work through the education on demand in your own time. All of it is free on Praxhub, and hours are lodged automatically with the RACGP and AMA CPD Home within 24 hours.
GPs, practice nurses, practice managers and practice owners: you can run the patient identification activity yourself through Praxhub, or complete the expression of interest form on this page and a Nurse Educator will get in touch to talk through how they can support your practice.
What's involved
The TargeT2D program includes three key elements
A case-based session on treatment intensification in T2D. Including an expert panel Q&A.
Seven short-form activities providing practical, case-based guidance to help GPs close practice gaps by applying Australian T2D recommendations for routine practice.
Identify and recall clearly defined at-risk patient cohorts with our patient identification activity (earn Measuring Outcomes hours) - with guidance from a dedicated Nurse Educator from the Wellness Clinical Services Registered Nurse team.
Description:
In this webinar, an expert multidisciplinary panel will apply Australian T2D guidance to a framework for identifying and managing patients with T2D who can benefit from clinical review or treatment intensification, from newly diagnosed patients requiring early, individualised management through to those with persistent above-target glycaemia despite established treatment.¹⁻² Through four patient cases, the panel will explore individualised HbA1c targets, early risk-factor management, therapeutic inertia, treatment initiation and intensification, the role of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), cardiorenal risk, monitoring, and recall.¹⁻²
Features a highly interactive, live Q&A with an expert panel.
Learning outcomes:
-
Apply individualised glycaemic targets and risk assessment to identify patients with T2D requiring treatment initiation or intensification, recognising therapeutic inertia.
-
Select glucose-lowering therapy according to patient characteristics - glycaemic requirements, cardiovascular disease, chronic kidney disease, heart failure, weight and hypoglycaemia risk.
-
Apply current Australian guidelines and PBS requirements when selecting therapy, including SGLT2 inhibitors and GLP-1 receptor agonists.
-
Implement monitoring, recall and reassessment strategies for patients with T2D who are overdue for review.
Steering Committee:
Prof Richard MacIsaac
Endocrinologist
A/Prof Ralph Audehm
General Practitioner & Medical Educator
Dr Romarna Dichiera
General Practitioner & Medical Educator
Ideal for: General Practitioners & Practice Nurses
ID: 43088
ID: 2499
ID: 1689110
CPD Webinar w. Live Q&A
Wednesday 11 November 2026
7:30-9:00pm (ACT, NSW, TAS, VIC)
7:00-8:30pm (SA)
6:30-8:00pm (QLD)
6:00-7:30pm (NT)
4:30-6:00pm (WA)
This CPD Program may also qualify as a Quality Improvement (QI) activity for general practices, supporting better patient outcomes, and clinic accreditation.
Supported Patient Identification Activity
Enrol your clinic in this CPD-accredited patient identification and recall program
In-practice and virtual support options available.
TargeT2D's patient identification activity enables clinicians to apply their new knowledge in a real-world setting with the support of a Wellness Clinical Services Nurse Educator.
Driven by the practice staff using the practice's clinical software, the patient identification process triggers a clinical review. It doesn't determine treatment. Every management decision stays with the treating clinician.
Up to 5 Measuring Outcomes CPD hours can be recorded for each general practitioner who participates in the patient identification activity.
TargeT2D CPD Shorts - Designed to fit your busy schedule
Quick, highly focused accredited CPD activities that deep-dive on some of the key themes of the TargeT2D program. Each comprises a quick video, accompanied by a short Reviewing Performance questionnaire.
This series of seven short-form activities provide practical, case-based guidance to help GPs close practice gaps by applying Australian T2D recommendations for routine practice. The activities address above-target HbA1c and therapeutic inertia, individualised treatment selection, SGLT2is and GLP-1 RAs treatment pathways, monitoring and recall, and shared decision-making with patients, and practical counselling when initiating a GLP-1 RA.
Pick and choose your topics and learn in any order you like.
?? mins
HbA1c can be used to diagnose diabetes, but a single result in someone without symptoms isn't enough to confirm it. The presenters walk through the risk factors to ask about, including family history, exercise, comorbidities, medications that can raise blood glucose, and the frequency of testing based on their HbA1c target levels.
?? mins
Several factors shape the choice of glucose-lowering treatment, including patient characteristics and comorbidities such as chronic kidney disease or heart disease. Learn how to weigh these factors and how to apply the patient-centred prescribing algorithm.
?? mins
This video explains how to navigate PBS criteria for GLP-1 RAs when first-line therapy is insufficient. It covers what to review when HbA1c remains above target on an SGLT2 inhibitor, the case for starting combination therapy early, and the PBS rules for switching between or combining these agents.
?? mins
Learn about the value of explaining prevention to patients, building planned care around a care plan, and using the practice database to identify and recall patients who are overdue for an HbA1c.
?? mins
An endocrinologist and a GP share practical strategies to help patients stay on their medications. They discuss collaborating with pharmacists and using My Health Record to identify missed repeats and address the reasons for them.
?? mins
Patients who know what to expect from a GLP-1 RA are more likely to keep taking it. Learn how to prepare patients for treatment, manage gastrointestinal side effects and decide when to hold off on up-titration if nausea persists.
?? mins
Should older patients with type 2 diabetes who already use insulin be considered for a GLP-1 RA? This video compares the two approaches, including hypoglycaemia risk, weight and injection frequency.
Continuing Professional Development (CPD) Details
This program consists of several separate but complementary activities that may be completed in any order. However, regarding the webinar, please complete the associated Reviewing Performance component before attending the webinar or watching the on-demand recording.
Clinicians who participate in this program can earn up to 11 CPD hours - including 1.5 hours Educational Activities, 5 hours Measuring Outcomes and 4.5 hours Reviewing Performance.
Hours will be lodged for RACGP, AMA's CPD Home, and ACRRM members. All learners will receive certificates of completion for each activity they complete, which may be used for the purpose of hours lodgement with their nominated CPDHome.
Automatic hours lodgement
RACGP and AMA CPDHome members can now enjoy the convenience of rapid, automatic EA hours lodgement for this education. See your completed hours lodged within 24 hours.*
* Requires correct membership details.
Update yours now >
Please note that any additional reading or learning connected to this activity can be self recorded with your CPD body.
Praxhub is an accredited Major Provider under the RACGP CPD Program.
Praxhub is a Certified Learning Provider under the AMA's CPDHome CPD Program.
Interested in the TargeT2D supported Patient Identification Activity?
Maximise the impact of your patient identification activity with the support of a highly experienced Nurse Educator from Wellness Clinical Services. Complete the form below and the team will be in touch to assess your eligibility for in-clinic or virtual support.
If you have questions regarding Praxhub's collection or use of your information, please visit our Terms of Use or contact privacy@praxhub.com
Praxhub acknowledges Novo Nordisk for its support of this education. The sponsor has provided no input into the content of this education.
References:
-
RACGP. Management of type 2 diabetes: A handbook for general practice. 2026.
-
Australian Diabetes Society. Australian Type 2 Diabetes Glycaemic Management Algorithm. 2026.
-
Usherwood T. Therapeutic inertia. Aust Prescr. 2024;47(1):15-19.
-
Imai C, Li L, Hardie RA, Georgiou A. Adherence to guideline-recommended HbA1c testing frequency and better outcomes in patients with type 2 diabetes: a 5-year retrospective cohort study in Australian general practice. BMJ Qual Saf. 2021;30(9):706-714.
-
Imai C, Li L, Hardie RA, Pearce C, Georgiou A. Patient and practice factors associated with HbA1c testing frequency in patients with type 2 diabetes: a retrospective cohort study in Australian general practice. Aust J Prim Health. 2023;29(5):520-526.
Approval